Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MEST intronic transcript 1, antisense RNA (MESTIT1) is a long non-coding RNA transcribed from the paternal allele within an intron of the MEST gene but in the opposite orientation. It shares a promoter region with one of the MEST gene’s promoters and is mostly expressed in the testis and mature spermatozoa, suggesting roles in development and imprinting. As a natural antisense transcript (NAT), MESTIT1 likely modulates MEST gene expression via chromatin modification, transcript masking, or transcriptional interference, mechanisms typical for lncRNAs involved in epigenetic regulation[1][2][4][5]. Disease associations are proposed for Silver-Russell syndrome 1 and glioma susceptibility, but it is not regarded as a classic therapeutic target[1]. Note: - MESTIT1 does not encode a protein and is not considered a direct druggable target. - Its principal role is regulatory, mainly through epigenetic effects on the MEST gene and control of allele-specific expression[1][2][4]. - No direct drugs, mechanisms, or biomarker roles are established for this transcript as of the search and current knowledge.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MEST intronic transcript 1, antisense RNA (MESTIT1).